First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum
Julia Fricke, Frida Westerbergh, Lisa McDougall, Chiara Favaretto, Emanuel Christ, Guillaume Nicolas, Susanne Geistlich, Francesca Borgna, Melpomeni Fani, Peter Bernhardt, Nicholas P. van der Meulen, Cristina Müller, Roger Schibli, Damian Wild
Topics & Concepts
MedicineDOTAAntagonistSomatostatin receptorIleumSomatostatinNeuroendocrine tumourInternal medicinePharmacologyReceptorChemistryChelationOrganic chemistryNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesPancreatic and Hepatic Oncology Research